DexCom CFO Departs; Interim Appointed, New Directors Elected

Ticker: DXCM · Form: 8-K · Filed: 2025-09-16T00:00:00.000Z

Sentiment: neutral

Topics: executive-departure, board-changes, interim-cfo

Related Tickers: DXCM

TL;DR

CFO OUT, interim IN. New board members join. #leadershipchange

AI Summary

DexCom, Inc. announced on September 14, 2025, the departure of its Chief Financial Officer, Parth Desai. The company has appointed Jerrod Hill as the interim CFO. Additionally, the board of directors has elected two new independent directors, Kevin J. McNamara and Steven J. Shulman, effective September 14, 2025.

Why It Matters

The departure of a CFO and the appointment of new directors can signal changes in financial strategy or governance, impacting investor confidence and future performance.

Risk Assessment

Risk Level: medium — Changes in key executive positions and board composition can introduce uncertainty regarding future strategy and financial management.

Key Players & Entities

FAQ

Who has been appointed as the interim Chief Financial Officer of DexCom, Inc.?

Jerrod Hill has been appointed as the interim Chief Financial Officer.

When was the departure of Parth Desai as CFO announced?

The departure was reported as of September 14, 2025.

Who are the new independent directors elected to DexCom's board?

Kevin J. McNamara and Steven J. Shulman have been elected as new independent directors.

What is DexCom, Inc.'s principal executive office address?

DexCom, Inc.'s principal executive offices are located at 6340 Sequence Drive, San Diego, CA 92121.

What is the exact date of the earliest event reported in this 8-K filing?

The date of the earliest event reported is September 14, 2025.

From the Filing

0001093557-25-000257.txt : 20250916 0001093557-25-000257.hdr.sgml : 20250916 20250915193047 ACCESSION NUMBER: 0001093557-25-000257 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20250914 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers FILED AS OF DATE: 20250916 DATE AS OF CHANGE: 20250915 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DEXCOM INC CENTRAL INDEX KEY: 0001093557 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 330857544 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-51222 FILM NUMBER: 251315432 BUSINESS ADDRESS: STREET 1: 6340 SEQUENCE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8582000200 MAIL ADDRESS: STREET 1: 6340 SEQUENCE DRIVE CITY: SAN DIEGO STATE: CA ZIP: 92121 8-K 1 dxcm-20250914.htm 8-K dxcm-20250914 false 0001093557 0001093557 2025-09-14 2025-09-14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): September 14, 2025 DEXCOM, INC. (Exact Name of the Registrant as Specified in Its Charter) Delaware 000-51222 33-0857544 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.) 6340 Sequence Drive , San Diego , CA 92121 (Address of Principal Executive Offices) ( Zip Code) ( 858 ) 200-0200 (Registrant’s Telephone Number, Including Area Code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))  Securities registered pursuant to Section 12(b) of the Act: Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, $0.001 Par Value Per Share DXCM Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐ ITEM 5.02.    DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS. Effective September 14, 2025, Kevin R. Sayer, Chief Executive Officer (principal executive officer) and Chairman of the Board of DexCom, Inc. (“Dexcom” or the “Company”) is taking a temporary medical leave of absence. Accordingly, effective September 14, 2025, Dexcom’s Board of Directors (the “Board”) appointed Jacob S. Leach, President and Chief Operating Officer, to serve as Dexcom’s interim principal executive officer, in addition to his current duties. In addition, Mark Foletta, Lead Independent Director of the Board, was appointed to serve as Dexcom’s interim chairman of the Board. Messrs. Leach and Foletta will

View on Read The Filing